Pimonidazole

Synonyms: Ro 03-8799

Pimonidazole (Ro 03-8799) is a novel hypoxia marker used for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma.

Pimonidazole Chemical Structure

Pimonidazole Chemical Structure

CAS: 70132-50-2

Purity & Quality Control

Batch: S991901 DMSO] 51 mg/mL] false] Ethanol] 51 mg/mL] false] Water] Insoluble] false Purity: 99.52%
99.52

Pimonidazole Related Products

Biological Activity

Description Pimonidazole (Ro 03-8799) is a novel hypoxia marker used for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma.
In vitro
In vitro

Pimonidazole has radio-sensitivity and recovery capacity from radiation-induced damage depend on p53 status of the tumor cell.<sup><a class="sref" href="#s_ref">[3]</a></sup>

Cell Research Cell lines HMV-II human malignant melanoma cells
Concentrations 0.5 mM
Incubation Time 1–4 h
Method
HMV-II cells are seeded by 2,000 cells per well in 96-well culture plates, allowed to adhere for 30 hr in a humidified atmosphere with 5% CO<sub>2</sub> at 37 C, and followed by incubation in a hypoxic condition of 100% N2 set in a glass desicator for 18 hr. The liposomal Pmz or free-Pmz is applied in 100 μL of degassed medium and incubated for 3 hr in a hypoxic condition of 100% N2 set in a glass desicator. After X-ray irradiation, the cells are incubated for 3 hr in a humidified atmosphere with 5% CO2 at 37 C.  The cells are confirmed to survive according to either morphological observation or cell viability assay using the redox indicator WST-8.
In Vivo
In vivo

Pimonidazole can overcome radiation resistance in hypoxiaby melanoma cells, which is enhanced by liposome modification.<sup><a class="sref" href="#s_ref">[2]</a></sup>

Animal Research Animal Models Human head and neck cancer xenograft model mice (BALB/c athymic nude mice; inoculated with FaDu cells)
Dosages 200 mg/kg
Administration IOCV
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03718650 Withdrawn
Pancreatic Cancer|Resectable Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute|Varian Medical Systems
April 1 2021 Early Phase 1
NCT03410420 Suspended
Aortic Aneurysm Thoracic
University of Maryland Baltimore
October 1 2018 Phase 1
NCT03262311 Completed
Cancer
Institute of Cancer Research United Kingdom
November 10 2017 Not Applicable
NCT02624115 Completed
Colon Rectal Cancer Adenocarcinoma
University Health Network Toronto
May 1 2016 --
NCT02095249 Active not recruiting
Prostate Cancer
University Health Network Toronto
September 2014 Not Applicable
NCT00374517 Withdrawn
Refractory Pulmonary Tuberculosis
National Institute of Allergy and Infectious Diseases (NIAID)|International Tuberculosis Research Center|National Institutes of Health Clinical Center (CC)
September 5 2006 Phase 2

Chemical Information & Solubility

Molecular Weight 254.29 Formula

C11H18N4O3

CAS No. 70132-50-2 SDF --
Smiles OC(CN1CCCCC1)C[N]2C=CN=C2[N+]([O-])=O
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 51 mg/mL ( (200.55 mM); Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 51 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Pimonidazole | Pimonidazole supplier | purchase Pimonidazole | Pimonidazole cost | Pimonidazole manufacturer | order Pimonidazole | Pimonidazole distributor